Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.85 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.85 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.85 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.85 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.85 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glimepiride SCHEMBL14965363 | 0.92 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL16084 | 0.92 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL16086 | 0.92 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL1331215 | 0.92 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL6381985 | 0.91 | CYP2C9 (0.95) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL5081711 | 0.91 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL20877218 | 0.91 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11189249 | 0.91 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL18157019 | 0.90 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL19096540 | 0.85 | MEN1 (0.73) | CYP2C9ABCC3ABCC4ABCB11HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2019-09-19 | — | — | US | disclosed |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | EMPIRIKO CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EMPIRIKO CORPORATION | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190283010-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | CYP2C9 4/4885ABCC3 514/4885ABCC4 658/4885 |
| US-20160303553-A1 | EX VIVO METHODS FOR PREDICTING AND CONFIRMING IN VIVO METABOLISM OF PHARMACEUTICALLY ACTIVE COMPOUNDS | CYP3A43, CYP3A4, CYP2D6 | CYP2C9 4/4885ABCC3 514/4885ABCC4 658/4885 |
| US-10265692-B2 | Ex vivo methods for predicting and confirming in vivo metabolism of pharmaceutically active compounds | CYP3A43, CYP3A4, CYP2D6 | CYP2C9 4/4885ABCC3 514/4885ABCC4 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.